Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552449 | 0.91 | ENPP2 (0.54) | ENPP2MAOBLOXL2MRGPRX4PNMT | |
| SCHEMBL2901465 | 0.83 | ENPP2 (0.54) | ENPP2MAOBLOXL2MRGPRX4PNMT | |
| SCHEMBL8256843 | 0.82 | MAOB (0.44) | MAOBMRGPRX4ALDH1A1CYP3A4IDO1 | |
| SCHEMBL30041293 | 0.82 | MAOB (0.44) | MAOBMRGPRX4ALDH1A1CYP3A4IDO1 | |
| SCHEMBL8299779 | 0.80 | IDO1 (0.56) | MAOBALDH1A1IDO1 | |
| SCHEMBL17733685 | 0.79 | TDP1 (0.42) | ENPP2MAOBALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL30966755 | 0.79 | LOXL2 (0.47) | ENPP2MAOBLOXL2MRGPRX4PNMT | |
| SCHEMBL29264560 | 0.79 | LOXL2 (0.47) | ENPP2MAOBLOXL2MRGPRX4PNMT | |
| SCHEMBL17214615 | 0.79 | ENPP2 (0.50) | ENPP2MAOBLOXL2MRGPRX4PNMT | |
| SCHEMBL22519891 | 0.79 | CYP3A4 (0.55) | ENPP2MAOBPNMTCYP3A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-2195296-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040290-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | ENPP2 227/4885MAOB 1669/4885LOXL2 3115/4885 |
| US-20090088451-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | ENPP2 609/4885MAOB 225/4885LOXL2 3510/4885 |
| US-20120136018-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | ENPP2 609/4885MAOB 225/4885LOXL2 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.